Lyndra Therapeutics Stock

Lyndra Therepeutics creates therapies for long-term drug release in an oral dose form.

Sign up today and learn more about Lyndra Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Lyndra Therapeutics Stock

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Funding History

July 2016$5.9M
April 2017$23.0M
February 2019$60.9M
July 2019$13.0M
June 2021$60.5M
June 2023$20.3M
December 2023$101M

Management

Executive Chairman & Co-Founder

Amy Schulman

Co-Founder

Colin R. Gardner

CEO, President & Board Member

Patricia Hurter

Chief Engineering Officer

Ray Knox

COO

Jessica Ballinger

Chief Technology Officer

Orn Almarsson

Chief Financial Officer

Klas Holmlund

Chief Manufacturing Officer

Raymond Knox

Co-founder & Member of the Board of Directors

Giovanni Traverso

Chairwoman of the Board of Directors

Catherine B. Reynolds

Scientific Fellow

Stephen Zale

Member of the Board of Directors

Amy Schulman

Senior Director of Engineering

Tyler Grant

Chief Medical Officer

Richard Scranton

Chief Engineering Officer

Raymond Knox

Member of the Board of Directors

Zafrira Avnur

Chief Manufacturing Officer

Ray Knox

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo